These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34216312)

  • 1. Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern.
    Tsujimura T; Iida O; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Matsuda Y; Hata Y; Uematsu H; Toyoshima T; Higashino N; Mano T
    CVIR Endovasc; 2021 Jul; 4(1):56. PubMed ID: 34216312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
    Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
    J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
    Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
    JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of recurrence based on intravascular ultrasound findings after Eluvia placement in symptomatic peripheral arterial disease: A retrospective study.
    Yamada T; Tokuda T; Yoshioka N; Koyama A; Nishikawa R; Shimamura K; Aoyama T
    Health Sci Rep; 2023 Aug; 6(8):e1481. PubMed ID: 37547358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
    Gasior P; Cheng Y; Valencia AF; McGregor J; Conditt GB; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28487355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
    Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
    Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eluvia drug-eluting vascular stent system for the treatment of symptomatic femoropopliteal lesions.
    Müller-Hülsbeck S; Hopf-Jensen S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J; Gray WA
    Future Cardiol; 2018 May; 14(3):207-213. PubMed ID: 29631434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Low Echoic Area" around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease.
    Soga Y; Ando K
    SAGE Open Med Case Rep; 2021; 9():2050313X211014519. PubMed ID: 34026211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
    Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
    J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration.
    Iida O; Takahara M; Soga Y; Yamaoka T; Fujihara M; Kawasaki D; Ichihashi S; Kozuki A; Nanto S; Sakata Y; Mano T;
    JACC Cardiovasc Interv; 2022 Mar; 15(6):630-638. PubMed ID: 35331454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of pseudoaneurysm after endovascular therapy with atherectomy and paclitaxel-coated balloon for superficial femoral artery lesion.
    Tsujimura T; Ishihara T; Osamu I; Yoshida M; Nakazato T; Ozaki T; Asai M; Masuda M; Okamoto S; Nanto K; Matsuda Y; Hata Y; Uematsu H; Higashino N; Nakao S; Kusuda M; Kitabayashi K; Mano T
    J Cardiol Cases; 2024 Jul; 30(1):20-23. PubMed ID: 39007041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents.
    Soga Y; Fujihara M; Iida O; Kawasaki D; Hirano K; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Gray WA; Müller-Hülsbeck S
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):215-222. PubMed ID: 31690980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries.
    Sakamoto A; Torii S; Jinnouchi H; Fuller D; Cornelissen A; Sato Y; Kuntz S; Mori M; Kawakami R; Kawai K; Fernandez R; Paek KH; Gadhoke N; Guo L; Kolodgie FD; Young B; Ragheb A; Virmani R; Finn AV
    J Vasc Interv Radiol; 2021 Jun; 32(6):792-801.e5. PubMed ID: 33677117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1832-1838. PubMed ID: 28948322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of polymer-coated paclitaxel-eluting stent implanted for diffuse and calcified superficial femoral artery stenotic lesions: Insights from a patient on hemodialysis.
    Yoshioka N; Takagi K; Tokuda T; Morita Y; Morishima I
    SAGE Open Med Case Rep; 2021; 9():2050313X211025929. PubMed ID: 34178357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Results of Eluvia™ Paclitaxel-Eluting Stent in External Iliac and Femoropopliteal Lesions.
    Elens M; Verhelst R; Possoz J; Mastrobuoni S; Lacroix V; Astarci P
    Surg Technol Int; 2017 Nov; 31():162-167. PubMed ID: 29121693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.